Researchers conducted a clinical trial to compare two different three-drug combinations for managing type 2 diabetes. The study involved 133 adults in South Korea whose blood sugar levels were not adequately controlled with their current medications (a DPP-4 inhibitor plus metformin). One group received pioglitazone added to alogliptin and metformin, while the other group received dapagliflozin added to alogliptin and metformin. The main goal was to see if these combinations were similarly effective at lowering HbA1c (a measure of average blood sugar) over 26 weeks.
This information comes from a trial registration record, not from published results. The record does not contain any data on how well the treatments worked, what side effects occurred, or whether participants completed the study. The overall time participants were in the study was up to 36 weeks, but the key effectiveness measurement was planned for the 26-week mark.
The main reason to be careful is that we cannot draw any conclusions about these treatments from this record. It simply tells us a study was planned and conducted. We do not know if one drug combination was better, worse, or the same as the other in terms of lowering blood sugar or causing side effects.
Readers should understand that this is a notice that a study happened, not a report of its findings. Until the actual results are published in a medical journal, we have no information on the outcomes. Patients should not change their medications based on this trial record and should continue following their doctor's advice.